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The production of two regulators of the inflammatory response, interleukin 10 (IL-10) and tumor necrosis factor α (TNFα), has
been found to be deeply deregulated in SLE patients, suggesting that these cytokines may be involved in the pathogenesis of the
disease. Genetic polymorphisms at the promoter regions of IL-10 and TNFα genes have been associated with diﬀerent constitutive
and induced cytokine production. Given that individual steady-state levels of these molecules may deviate an initial immune
response towards diﬀerent forms of lymphocyte activation, functional genetic variants in their promoters could influence the
development of SLE. The present review summarizes the information previously reported about the involvement of IL-10 and
TNFα genetic variants on SLE appearance, clinical phenotype, and outcome. We show that, in spite of the heterogeneity of the
populations studied, the existing knowledge points towards a relevant role of IL-10 and TNFα genotypes in SLE.
1. Introduction
In spite of its unknown etiology, it is accepted that
genetics and environmental factors contribute to systemic
lupus erythematosus (SLE) susceptibility and outcome.
The levels of various cytokines have been found elevated
in SLE patients; so they have been considered essential
elements in the etiopathology of the disease. Given that
the production of these molecules is controlled at genetic
level, functional polymorphisms in their promoters could
influence the development and severity of the disease. In
particular, the production of interleukin 10 (IL-10) and
tumor necrosis factor α (TNFα), two mutually regulated
cytokines that play complex and predominantly opposite
roles in systemic inflammatory responses, has been found
to be deregulated in SLE patients (Figure 1). Besides its
stimulated production, various cell types are constitutively
capable of producing detectable amounts of these cytokines,
mainly cells of myeloid origin and less abundantly T
and B lymphocytes. It has been reported that individ-
ual steady-state levels of these molecules may deviate an
initial immune response towards diﬀerent forms of T
cell activation, influencing the likelihood to transform a
limited autoimmune response into an autoimmune dis-
ease.
Several evidences suggest that IL-10 could be a strong
candidate gene influencing SLE susceptibility. IL-10 is an
important immunoregulatory cytokine that inhibits T cell
function by suppressing the expression of proinflamma-
tory cytokines such as TNFα, IL-1, IL-6, IL-8, and IL-
12 [1, 2]. It also inhibits antigen presenting cells by
downregulating major histocompatibility complex class II
(MHC-II) and B7 expression [3]. In addition to these
inhibitory actions, IL-10 promotes B-cell-mediated func-
tions, enhancing survival, proliferation, diﬀerentiation, and
antibody production [4]. Hence, increased production of IL-
10 could thus explain B cell hyperactivity and autoantibody
production, two main features of the immune dysregulation
in SLE. In fact, elevated levels of this molecule have been
currently reported in SLE patients, frequently associated
with indicators of disease activity [5, 6]. Moreover, it
has been demonstrated that IL-10 plays an important
role in murine lupus. Ishida et al. [7] reported that
continuous administration of anti IL-10 antibodies in the
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Figure 1: Interplay between IL-10 and TNFα in SLE. This figure represents a simplified model of the complex relationship between IL-10
and TNFα in lupus disease. Both cytokines are produced by multiple cells types of the innate and adaptative immune system, in particular
dendritic cells (DCs), monocytes/macrophages, and specific eﬀector T cells. Th1 cells produce the proinflammatory cytokine TNFα which
activates DCs and other antigen presenting cells (APCs), and induces the production of IL-10. In addition, TNFα promotes inflammation
and apoptosis, generating neoantigens that could result in autoantibody production. On the other hand, IL-10, a Th2 cytokine, antagonize
Th1 diﬀerentiation and inhibits APCs and T cells. Conversely, IL-10 is a potent stimulator of B cell proliferation, diﬀerentiation and antibody
production. Thus, B cell activation in presence of neo-antigens may led to autoantibody secretion and immune complexes formation, thus
resulting in tissue damage aﬀecting diverse organs. STAT; signal transducer and activator of transcription.
murine lupus model New Zealand black/white (NZB/W)
F1 delayed the onset of autoimmunity and improved the
survival rate from 10 to 80%. Interestingly, Llorente et al.
[8] demonstrated that constitutive IL-10 production by
monocytes and B cells in healthy members of multicase
families with SLE was significantly higher than that of
healthy unrelated controls, but was similar to that of SLE
patients, thus suggesting that a genetically controlled high
innate IL-10 production may predispose to SLE develop-
ment.
In the same way, TNFα is a well-known cytokine for
its role in the regulation of inflammation and apopto-
sis, two processes involved in the pathogenesis of SLE.
This molecule stimulates the production of inflammatory
cytokines, enhances neutrophil activation and expression
of adhesion molecules and acts as a costimulator for T-
cell activation and antibody production. Accordingly, in
vivo and in vitro studies demonstrated that high levels of
TNFα lead to exacerbation of the inflammatory response.
These eﬀects, together with its potent immunomodulator
activities [9–11], could support the involvement of TNFα
in the pathogenesis of SLE [12]. However, initial studies
in murine models of SLE showed contradictory results,
probably because diﬀerent strains of lupus prone mice have
diﬀerent phenotypic features. Thus, whereas the (NZB/W)
F1 strain produces relatively low level of TNFα and treatment
with recombinant TNFα caused a significant delay in the
onset of nephritis and an improved survival rate [13], MRL-
lpr/lpr and BXSB strains constitutively produce relatively
high amounts of TNFα, being its eﬀect deleterious in the
outcome of the disease [14].
Nevertheless, a number of studies showed higher serum
levels of TNFα in SLE patients compared with controls,
which were frequently linked to SLE activity [15] or to
specific immunological or clinical features, such as elevated
autoantibody production [10, 11, 16]. All these data lead to
suspect that TNFα has an important role in SLE susceptibility
or outcome [17, 18].
Journal of Biomedicine and Biotechnology 3
Table 1: Main functional IL-10 and TNFα SNPs involved in SLE.
IL-10 TNFα
Functional polymorphism −1082 A/G −308G/A
rs number 1800896 1800629
High producer allele −1082G∗ −308A∗
Population frequency of high
producer allele(1)
North/Centre European and
North American [32, 40, 44, 46]
0.43–0.52 0.11–0.17
South European [30, 36, 39, 45] 0.29–0.40 0.12–0.14
South American [31, 37, 38, 42] 0.29–0.35 0.08–0.03
Asian [29, 34, 35, 41, 43] 0.04–0.06 0.10–0.14
(1)Ranges of allele frequency in healthy population.
2. Functional IL-10 and TNFαGenetic
Polymorphisms
Human IL-10, encoded by a gene located at chromosome
1, is secreted by a variety of cell types in response to
several activation stimuli. This cytokine could be also
constitutively produced at low levels by immune cells, mainly
monocytes, macrophages and dendritic cells. In fact, in
contrast to many other cytokines, the synthesis of IL-10 is
regulated by the transcription factors Sp1 and Sp3, which
are constitutively expressed by diﬀerent cell types [19]. The
striking interindividual diﬀerences detected in IL-10 levels
at both in vivo constitutive and in vitro following cellular
stimulation [20], suggest that its production is genetically
controlled. A number of genetic polymorphisms at the
promoter region of the IL-10 gene have been reported,
some of them associated with diﬀerent constitutive and
induced cytokine production. Among them, the most widely
studied include two areas of multiple (CA)n repeats, the
microsatellites IL10.R (−4 Kb) and IL10.G (−1.1 Kb) [21, 22]
with probable association with IL-10 production, and three
single nucleotide polymorphisms (SNPs) located at −1082
(G/A), −819 (C/T) and −592 (C/A) positions upstream
of the transcription start site [23]. A complete linkage
disequilibrium exists between the alleles present at −819 and
−592 positions; so these polymorphisms occurred in tandem
and only three haplotypes have been found in Caucasian
populations (GCC, ACC and ATA). These SNPs have been
associated with variability in IL-10 production [24–26]
and carriers of the GCC/GCC genotype are considered as
genetically high producers, being −1082G the most relevant
allele [24, 27, 28] (Table 1) [29–46].
The gene encoding TNFα is located at the MHC class III
region, placed on chromosome 6p21. Similarly to IL-10, an
important genetic diversity at the TNFα promoter has been
detected. In vitro studies indicated that TNFα production
varied among diﬀerent alleles of the five microsatellite mark-
ers described (a, b, c, d and e). In addition, several SNPs have
been identified [47–49], being −308 G/A and −238 G/A the
most extensively examined. The polymorphic variant−238A
is associated with DR3 and DR7 in extended haplotypes
[50, 51], but no consistent data about their functionality were
reported. Polymorphism present at position−308, identified
by Wilson et al. [49], has been associated with diﬀerent
levels of cytokine production. The less common TNF2 allele
(−308A) has been related to higher TNFα transcription rate
than the TNF1 allele (−308G) after in vitro activation of
lymphocytes with diﬀerent stimuli [52, 53]. In vivo studies
on mRNA constitutive levels confirmed this association [54]
(Table 1). TNF2 is part of the extended haplotype HLA-A1-
B8-DR3-DQ2 [55], associated with high TNFα production
[56, 57] and with predisposition to several autoimmune
diseases. Nevertheless, carriage of TNF2 allele—in the pres-
ence or absence of other loci—leads to an increase in TNFα
production that could modify cytokine homeostasis in favor
of the development of pathogenic situations.
3. IL-10 Genetic Polymorphisms and
SLE Susceptibility
The IL-10 gene is situated in a major SLE susceptibility
locus (1q31-32) [58]. However, in spite of the considerable
number of genetic studies performed, no definitive result
about its involvement in SLE susceptibility was achieved.
Some works showed significant associations between IL-10
microsatellites or SNPs with SLE susceptibility or with the
development of certain clinical or immunological features,
while other studies indicated that these polymorphisms did
not appear to have any relevance in the disease (Table 2) [27–
31, 34, 45, 59–71]. With respect to microsatellite variants,
diﬀerent alleles of IL10.G have been reported to be associated
with SLE incidence in various populations. Thus, frequency
of IL10.G9 allele (21 CA repeats) was significantly decreased
in European [30, 66, 71] and Mexican-American [70] SLE
patients, whereas the long alleles IL10.G10, G11 and G13
(with a CA repeat number greater than 21) were significantly
increased in Mexican-American [70], Italian [30, 66] and
British [71] patients respectively. On the contrary, an
increase in IL10.G4 (short allele) was reported in Chinese
patients [29] whereas no significant diﬀerences in IL10.G
alleles were detected in other cohorts [65, 68, 72, 73]. In
addition, a meta-analysis study showed only association of
the IL10.G11 allele with SLE susceptibility in the populations
analyzed (OR = 1.279; 95% CI: 1.027–1.593; P = .028)
[62]. It has been reported that LPS-stimulated cells from
individuals carriers of the IL10.G allele with 26 CA repeats
presented higher IL-10 production than those from carriers
of short alleles [25], suggesting that long alleles might be
responsible for a high IL-10 production. Thus, accordingly to
these data, high IL-10 producer genotypes (with more than
21 CA repeats) could be associated with SLE susceptibility,
while presence of short alleles could confer a protective eﬀect
[60, 66].
Conflicting results were also obtained after examining
the possible association between SLE susceptibility and SNPs
at −1082, −819 and −592 positions of IL-10 gene in the
diﬀerent populations in which they were investigated. The
frequency of high IL-10 producers (carriers of −1082G allele
or GCC haplotype) was found to be increased in several
works with Asian [62, 74] or European [59, 75] patients,
4 Journal of Biomedicine and Biotechnology
Table 2: Summary of association studies of IL-10 promoter polymorphisms with SLE.
Reference Population SLE/controls Polymorphisms Associations
Rosado et al. (2008)
[59]
Spanish 116/51
IL10G, IL10R
−1082/ − 819/ − 592
No association of microsatellites
Increased GCC in SLE
Guarnizo-Zuccardi
et al. (2007) [31]
Colombian 120/102 −1082/ − 819/ − 592 No association
Chen et al. (2006)
[60]
Taiwanese 237/304 IL10G
Increased G9 and decreased G8 in SLE.
G13 associated with anticardiolipin IgM
antibodies and G8 with neurologic
aﬀectation.
Sung et al. (2006)
[61]
Korean 350/330 −592 No association with susceptibility−592C associated with SLE activity
Nath et al. (2005)
[62]
Meta-analysis 2391/3483
IL10G/IL10R
−1082/ − 819/ − 592
Increased G11 in whole population
Increased −1082G in Asian populations
Khoa et al. (2005)
[63]
Vietnamese 64/57 −1082 Increased −1082G in SLE
Chong et al. (2004)
[29]
Chinese
550/689
554/708
IL10G, IL10R
−1082/ − 819/ − 592
Increased G4 in SLE
Increased −592CC in SLE
Schotte et al. (2004)
[65]
German 210/158 IL10G, IL10R
No association with susceptibility
R2-G14 associated with anti-Sm
antibodies
Suarez et al. (2004)
[45]
Spanish 248/343 −1082,−819,−592
No association with susceptibility.
Association of −1082G with discoid
lesions
Dijstelbloem et al.
(2002) [64]
Caucasian 180/163 −1082 No association
D’Alfonso et al.
(2002) [66]
Italian 217/173
−1082/ − 851/ − 592
IL10G
Association of IL10G “long alleles” with
SLE
D’Alfonso et al.
(2000) [30]
Italian 159/164 IL10G, IL10R Increased G11 and decreased G9 in SLE
van der Linden et al.
(2000) [67]
Mixed 44/125 −1082/ − 851/ − 592 No association
Alarcon-Riquelme
et al. (1999) [68]
Mexican 330/368 IL10G No association
Rood et al. (1999)
[28]
Dutch 92/162 −1082/ − 819/ − 592 Increased ATA in neuropsychiatric SLE
Crawley et al. (1999)
[69]
Anglo-saxon 120/274 −1082/ − 819/ − 592 No association
Mok et al. (1998)
[34]
Chinese 83/88 −1082/ − 819/ − 592 No association with susceptibility
Increased ATA in renal disease
Mehrian et al.
(1998) [70]
Mexican-American 158/220 IL10G Increased G10 and decreased G9 in SLE
Eskdale et al. (1997)
[71]
Anglo-Saxon 56/102 IL-10G, IL-10R Increased G13 and decreased G9 in SLE
Lazarus et al. (1997)
[27]
Anglo-Saxon 76/199 −1082/ − 819/ − 592 GCC associated with anti-SSa
although most of the studies performed in Caucasian
populations did not show significant associations [27, 31, 34,
45, 64, 67, 69, 76].
4. TNFαGenetic Polymorphisms and
SLE Susceptibility
Less controversial data exist with regard to TNFα SNPs, since
genotypes associated with high cytokine production have
been linked to SLE susceptibility in diﬀerent populations
(Table 3) [31, 38–46, 74, 77–90]. Thus, an increased risk
of developing SLE, independent of the HLA-DR genotype,
has been reported for carriers of TNF2 allele in Caucasian
[31, 44–46, 78, 81, 90], African American [91], Chinese [82,
85], Colombian [31, 38, 92] and Mexican [42] populations,
while no relation was found in a few works analyzing mestizo
Mexican [83], Caucasian [39, 84], African Americans [81] or
Asian [41, 60, 74, 85] cohorts. In fact, the allele-based com-
parisons of 21 studies [77], after stratification by ethnicity,
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Table 3: Summary of association studies of TNFα promoter polymorphisms with SLE.
Reference Population SLE/controls Polymorphisms Associations
Jime´nez-Morales
et al. (2009) [42]
Mexican 328/400 −238/ − 308 Increased −308A in SLE. No association
with −238.
Lin et al. (2009) [43] Taiwanese 162/213 −308
No association with susceptibility
−308A associated with malar rash,
discoid rash, photosensitivity, oral ulcers
and serositis.
Hirankarn et al.
(2007) [74]
Thai 154/154 −238/ − 308/ − 863 Increased −863A/ − 308G/ − 238G
haplotype in SLE
Guarnizo-Zuccardi
et al. (2007) [31]
Colombian 120/102 −308 Increased −308A in SLE and association
with anti-Sm and anti-SSa antibodies
Lee et al. (2006) [77] Meta-analysis 3060/4479 −308 Increased −308 AA in European, but not
in Asian populations
Schotte et al. (2005)
[78]
German Caucasian 205/157
microsatellites
−308 Increased TNFd1 and −308A in SLE
Takeuchi et al.
(2005) [79]
Japanese 61/111 microsatellites No association
Tobon et al. (2005)
[80]
Colombian 113/65 −308 No association
Parks et al. (2004)
[81]
North American 230/276 −238/ − 308 Increased −308A in Caucasians, but not
in African Americans
Azizah et al. (2004)
[82]
Chinese 70/59 −308
Increased −308A in SLE and associated
with central nervous system involvement
and with anti-SSb antibodies
Correa et al. (2004)
[38]
Colombian 100/430 −308 Increased −308A in SLE
Suarez et al. (2004)
[45]
Spanish 248/343 −308 Increased −308A in SLE and association
with anti-SSa antibodies
Rood et al. (2000)
[44]
Caucasian 99/177 −238/ − 308 Increased −308A in SLE
van der Linden et al.
(2001) [46]
Caucasian 91/253 −308 Increased −308A in SLE
Zun˜iga et al. (2001)
[83]
Mexican mestizo 51/55 −238/ − 308 No association with −308. Increased−238A in SLE
Tsuchiya et al.
(2001) [84]
Southern California 91 families −238/ − 308 No association
Wang et al. (1999)
[85]
Han ethnic group
(China)
89/70 −308
Increased −308A in SLE and associated
with anti-SSa antibodies and lupus
nephritis
Tarassi et al. (1998)
[86]
Greek 46/62 microsatellites
Increased TNF a11, a2, b3 in SLE (linkage
disequilibrium with HLA)
Hajeer et al. (1997)
[87]
Caucasian 91/109 microsatellites
Increased TNF a2, b3, d2 in SLE and
associated with photosensitivity and
Raynaud’s phenomenon
Chen et al. (1997)
[88]
Chinese 100/107 −308 No association
Rudwaleit et al.
(1996) [89]
Anglo-Saxon
South African
49 white
49 black
−238/ − 308 Increased −308A in white UK (linkage
disequilibrium with DR3)
DAlfonso et al.
(1996) [39]
Italian 123/199
microsatellites
−238/ − 308 No association
Fong et al. (1996)
[41]
Chinese 67/89 −308 No association
Danis et al. (1995)
[40]
Anglo-Saxon 40/57 −308 Increased −308A in SLE and associated
with DR3
Wilson et al. (1994)
[90]
Caucasian 81/168 −308 Increased −308A in SLE and associated
with anti-SSa/SSb autoantibodies
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detected a significant association of the −308A allele in
the European-derived groups, but not in Asian-derived
or African-derived populations. Conversely, no association
between −238 TNF SNP and SLE was observed in the great
majority of the populations analyzed [42, 44, 74, 81, 89, 92].
On the other hand, the influence of TNFα microsatellite
variants in SLE incidence has been poorly investigated.
Alleles a2, b3 and d2 have been found to be increased in
SLE patients from various European populations [86, 87, 93],
showing linkage disequilibrium with HLA-DR3 haplotypes
associated with SLE risk. On the contrary, no association was
found in a study with Japanese patients [79].
5. Influence of IL-10 and TNFαGenotypes on
Autoantibody Production
The presence of autoantibodies, mainly directed against
nuclear antigens (ANAs), is one of the most characteristic
features of SLE. It has been observed that the incidence of
ANAs is more frequent among nonaﬀected family members
of SLE patients than in the healthy population, suggesting
that presence of autoantibodies may be, at least in part,
genetically controlled [94–96]. The eﬀect of IL-10 genotypes
did not seem to be especially relevant, although it has
been reported an increased prevalence of antibodies against
several extractable nuclear antigens (anti-ENA) in patients
with the allele IL-10.G9 [71], and the presence of anti-Sm
antibodies was found significantly overrepresented among
patient carriers of G14 and G15 alleles and R2-G15 and R2-
G14 haplotypes [65].
On the other hand, an association of the high producer
TNFα genotypes (−308 AA or AG) with the presence of
autoantibodies has been consistently reported. It has been
described an association between carriage of the TNF2 allele
and presence of anti-SSa or anti-SSb antibodies [45, 82, 85].
This finding is in accordance with the increased frequency
of TNF2 allele reported in patients with cutaneous lupus
erythematosus [76, 97], congenital heart block [98] and
cutaneous neonatal lupus [99], all of them being pathologies
linked to the presence of anti-SSa antibodies. However,
it is important to consider that the actions of cytokines
may be profoundly conditioned by the presence of other
cytokines, and this is particularly true in the case of IL-10
and TNFα, two mutually regulated molecules which have
opposite roles in the inflammatory reactions. In fact, the
investigations about the eﬀect of combined IL-10 and TNFα
genotypes in SLE supported this interaction. Specifically,
the highest percentage of antibodies against SSa and SSb
was found among carriers of the combined genotype “low
IL10 (−1082AA-AG)/high TNFα (−308AA-AG)” [45], the
genotype linked to the highest TNFα production [100].
Association of high TNFα genotypes, alone or in combina-
tion, and autoantibody appearance has also been described
in patients with other autoimmune pathologies such as
inflammatory bowel disease or Sjo¨gren‘s syndrome [101–
103]. This eﬀect of TNFα could be mediated by its highly
proapoptotic activity since, as it has been reported, sera
from SLE patients react with proteins phosphorylated during
apoptosis [104], probably by recognising new epitopes
generated by phosphorylation or proteolysis [105]. Thus,
we can hypothesize that the proapoptotic properties of
elevated TNFα levels could not be counterbalanced by the
low amounts of IL-10 in patients with the high TNFα/low
IL-10 genotype, thus triggering an autoimmune response
to antigenically modified autoproteins generated during the
apoptotic process.
6. Genetic Polymorphisms and
Clinical Outcome
Increased circulating levels of IL-10 and TNFα have been
consistently reported in the sera of patients with SLE.
However, there were no definitive data on the association
of IL-10 or TNFα polymorphisms and specific clinical
manifestations, probably due to the heterogeneity of the
disease. For instance, renal involvement has been associated
with both high (GCC) [27, 106] and low (ATA) [107] IL-
10 producer genotypes. High prevalence of neuropsychiatric
[28] and cardiovascular disorders [108] has been reported
in patients with low genetic production whereas high IL-
10 production has been linked to an increased incidence of
serositis, hematological disorder [29], SLICC/ACR Damage
Index [61] and presence of discoid or mucocutaneous lesions
[45, 68]. This last association was supported by the increased
frequency of the high producer −1082G allele observed in
patients with discoid lupus erythematosus [45, 67] and by the
fact that cutaneous manifestations improved in SLE patients
under anti IL-10 monoclonal antibody treatment [109].
With respect to TNFα genotype, most works did not
find relevant relationships with clinical parameters, although
it has been reported an increased frequency of the TNF2
allele in patients with nephritis [85], central nervous system
involvement [82] and presence of malar rash, discoid lesions,
photosensitivity, oral ulcers or serositis [43]. However, it is
worth noting the interesting association detected between
TNFα genotype and clinical outcome after antimalarial
treatment. Antimalarial drugs (hydroxychloroquine, chloro-
quine, and quinacrine) have been widely used as disease-
modifying antirheumatic agents mainly in the treatment
of SLE and rheumatoid arthritis [110]. Nevertheless, their
beneficial mechanisms have not been fully defined. Several
in vitro experiments have demonstrated that antimalarials
decreased the production of proinflammatory cytokines
induced by LPS or CpG oligonucleotides in monocytes and
macrophages [111–114] by a nonlysosomotropic mecha-
nisms [115] and/or by blocking the interaction between
TLR9 and CpG in monocyte endosomes [116]. More
recently, this valuable antiinflammatory eﬀect has been
documented in patients with SLE, in whom antimalarial-
treatment has been shown to downregulate serum levels of
TNFα [100, 117]. But the most interesting finding was that
antimalarial eﬀect seems to be influenced by polymorphisms
of the genes encoding TNFα and IL-10. Specifically, the
greatest beneficial eﬀect of antimalarial treatment appeared
in patients carriers of the combined genotype low IL-10/high
TNFα, since they presented better clinical response, lower
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amount of circulating TNFα and increased number and
function of CD4+CD25high Treg cells [118] as compared with
other genotypes. Of note, antimalarial treated SLE patients
which were carriers of the opposite high IL-10/low TNFα
genotype, presented higher circulating IFNα levels, thus
suggesting an interesting relationship between TNFαand
IFNα in lupus disease [119].
7. Conclusions and Perspectives
It seems to be clear that carriage of the high producer
TNF2 allele is a risk factor for SLE appearance in Caucasian
populations. However, in spite of the wide number of studies
performed, conclusive data on the involvement of IL-10
genetic variants have not been obtained. Nevertheless, the
inverse relationship existing between both cytokines, could
determine a role for IL-10 in the phenotype and/or outcome
of the disease. SLE patients carriers of the high TNFα
genotype probably developed the disease due to the eﬀect of
environmental or genetic factors added to their high TNFα
production. The elevated levels of this cytokine may be
involved in diverse pathological mechanisms and, therefore,
a clinical benefit could be expected under a treatment that
diminishes TNFα production. In fact, a strong association
was found between carriage of this genotype, in combination
with low IL-10 producer alleles, and good response to
antimalarial therapy, a treatment that downregulated TNFα
levels. Thus, we would expect that carriage of the proinflam-
matory genotype low IL-10/ high TNFα may predispose to
develop anti-SSa/SSb antibodies and mild disease presenting
a good course under antimalarial therapy. In addition, the
conflicting data about the association of IL-10 and TNFα
genotypes with clinical features which were observed by
the various studies performed supports the heterogeneity of
the disease and the involvement of diverse etiopathogenic
factors. Thus, treatments and management of the disease
might be individualized depending on IL-10 and TNFα
genotypes.
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